ReviewOncology letters2025
Comprehensive treatment of intermediate and advanced primary hepatocellular carcinoma based on transcatheter arterial chemoembolization (Review).
Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy of lenvatinib combined with sintilimab and transcatheter arterial chemoembolization in conversion therapy for unresectable hepatocellular carcinoma.Pakistan journal of medical sciences · 2026Article
- High-sensitivity photoelectric sensing of apatinib for recurrent hepatocellular carcinoma in TACE.RSC advances · 2026Article
- Sarcopenia modifies the survival benefit of triple therapy versus TACE alone in elderly patients with unresectable hepatocellular carcinoma: A multicenter retrospective cohort study.Scientific reports · 2026Article
- Combination of locoregional and systemic therapy for hepatocellular carcinoma with portal vein tumor thrombus: a real-world retrospective study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hepatocellular carcinoma (HCC) represents a malignancy of notable clinical concern, marked by elevated global incidence and mortality rates. Despite advancements in therapeutic modalities, HCC management remains challenged by the insidious onset of early-stage disease and the limited efficacy of late-stage surgical interventions. Transcatheter arterial chemoembolization (TACE) has evolved as a pivotal intervention for HCC, with recent innovations fostering synergistic combination strategies to augment therapeutic outcomes. Synthesizing contemporary clinical evidence and anticipating future advancements in TACE-based multimodal approaches is imperative to refine therapeutic paradigms and optimize patient prognoses. The present review critically evaluates the current landscape of TACE-centered multimodal therapies and explores emerging innovations poised to redefine therapeutic frontiers in HCC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.